TSE:4507Pharmaceuticals
Shionogi (TSE:4507) Infectious Disease Progress Keeps Valuation Questions In Play
Why Shionogi stock is back on infectious disease investors’ radar
Shionogi (TSE:4507) has drawn fresh attention after Japan approved a pediatric regimen for its COVID-19 drug XOCOVA, and partner F2G reported positive Phase 3 OASIS results for olorofim, supporting progress in infectious disease treatments.
See our latest analysis for Shionogi.
Despite the steady stream of infectious disease updates, Shionogi’s short term share price performance has been weak. It has a 30 day share price return...